1、1AAM|THE U.S.GENERIC&BIOSIMILAR MEDICINES SAVINGS REPORT 2024The U.S.Generic&Biosimilar Medicines Savings ReportS E P T E M B E R 2 0 2 42AAM|THE U.S.GENERIC&BIOSIMILAR MEDICINES SAVINGS REPORT 2024INTRODUCTIONLetter From the President and CEOProtecting Patients for the Next 40 Years and BeyondOn th

2、e eve of the 40th anniversary of the Drug Price Competition and Patent Restoration Act,commonly known as the“Hatch-Waxman Act,”we stand at a critical crossroads.Will we enact policies that support another forty years of a vibrant generic market,enabling patients to access the medicines they need?Or

3、will we allow anti-competitive behavior and the suppression of generic medicines to continue?Will we fight to continue to provide low-cost medications to all patients,including the most vulnerable populations and those who need them most?Or will we force more manufacturers to exit markets and exacer

4、bate shortages of lifes-saving drugs?I am pleased to share AAMs latest annual savings report highlighting the overall value of the generic and biosimilar industry.This report is the culmination of a continued collaboration with the IQVIA Institute for the past 14 years.Together,generic and biosimila

5、r drugs represent a whopping 90 percent of all U.S.prescriptions for only 13 percent of spending.In the context of all healthcare spending,generics and biosimilars represent only one percent of the U.S.healthcare expenses.With manufacturing facilities located in nearly half of U.S.states from Califo

6、rnia,to New Jersey,from Illinois,to North Carolina and beyond todays generic drug industry makes it easier for patients to afford their medicines.We help employers pay for healthcare to keep our American workforce healthy,and we help health plans contain spending.Generic and biosimilar manufacturers